News

APO-Easy Genotyping kit for Alzheimer's Disease diagnostic

20 August 2024

Amoneta Diagnostics gains CE-marking for APO-Easy® Genotyping Kit under EU IVDR

Amoneta announces the CE-marking under the EU-IVDR of its APO-Easy® Genotyping Kit....

ALZEVIT Study – RCB No.: 2026-A00246-45

Decentralised national digital cohort for APOE genotyping and longitudinal characterisation of APOE ε4/ε4 homozygote trajectories, with a view to developing strategies for Alzheimer's disease.

Quick Contact

If you have any questions or need assistance, please do not hesitate to contact our team.

Send us an email :

Alzevit@firalis.com

+33 (0) 389 911 320

Amoneta Diagnostics gains CE-marking for APO-Easy® Genotyping Kit under EU IVDR

Search

Articles récents

Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch

Amoneta at CTAD 2024: Introducing our Research on Advancing Alzheimer’s Disease Stratification

Amoneta Diagnostics attends the AD/PD™ 2024 International Conference

Catégories

ALZEVIT

Resources

Useful links

Quick Contact

News

Amoneta Diagnostics gains CE-marking for APO-Easy® Genotyping Kit under EU IVDR

Search

Articles récents

Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch

Amoneta at CTAD 2024: Introducing our Research on Advancing Alzheimer’s Disease Stratification

Amoneta Diagnostics attends the AD/PD™ 2024 International Conference

Catégories

Tags

ALZEVIT

Resources

Useful links

Quick Contact